Rajeev Saggar

Chief Medical Officer
Dr. Saggar joined Liquidia in July 2022 and oversees all aspects of research, clinical development, medical affairs, and regulatory affairs for the company. He brings more than 20 years of experience as a practicing pulmonologist and has authored more than 60 peer-reviewed publications with scientific interests including pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD). Dr. Saggar has previously served as Interim Chief of the Division of Pulmonary Critical Care at University of Arizona, College of Medicine, Phoenix and the Medical Director of the Pulmonary Hypertension and Fibrosis Programs and Lung Transplant Program at Banner University Medical Center, Phoenix. In his role at Banner Medical Center, he served as a Principal Investigator in the pivotal INSPIRE study of YUTREPIA initiated in 2018. Just prior to joining Liquidia, Dr. Saggar served as Vice President of Clinical Development at Theravance Biopharma with oversight of all phases of clinical development across respiratory disease portfolio, including pulmonary fibrosis, allograft rejection, asthma, COPD, and COVID-19. Dr. Saggar received a M.D. degree from the University of California, Irvine. He completed his residency in Internal Medicine and fellowship in Pulmonary & Critical Care at the University of California, Irvine, as well as subspecialty training in pulmonary hypertension and lung transplantation at University of California, San Diego and University of California, Los Angeles, respectively.